We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$11.9B
AUM Growth
+$1.4B
(+13%)
Cap. Flow
+$748M
Cap. Flow
% of AUM
6.3%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
747
New
202
Increased
220
Reduced
153
Closed
161
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$134M |
| 2 |
STMicroelectronics
STM
|
+$103M |
| 3 |
Meta Platforms (Facebook)
META
|
+$89.9M |
| 4 |
MetLife
MET
|
+$71.9M |
| 5 |
Gilead Sciences
GILD
|
+$70.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TE Connectivity
TEL
|
+$161M |
| 2 |
Eli Lilly
LLY
|
+$153M |
| 3 |
MRSH
Marsh
MRSH
|
+$123M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$91.8M |
| 5 |
Electronic Arts
EA
|
+$79.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.43% |
| 2 | Technology | 17.4% |
| 3 | Industrials | 8.07% |
| 4 | Energy | 6.4% |
| 5 | Financials | 6.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ESPR
426
DELISTED
Esperion Therapeutics
ESPR
| $3.7M | 0.03% |
2,244,360
-2,805,448
| -56% | -$5.66M |
|
427
Aurinia Pharmaceuticals
AUPH
$2.07B
| $3.67M | 0.03% |
500,494
-113,572
| -18% | -$704K |
|
428
Replimune Group
REPL
$1.02B
| $3.65M | 0.03% |
332,943
+39,321
| +13% | +$399K |
|
429
Astera Labs
ALAB
$57.9B
| $3.64M | 0.03% |
69,396
+2,934
| +4% | +$138K |
|
|
CCRN
430
DELISTED
Cross Country Healthcare
CCRN
| $3.53M | 0.03% |
+262,603
| New | +$3.87M |
|
431
Neurogene
NGNE
$711M
| $3.49M | 0.03% |
+83,088
| New | +$3.22M |
|
|
OTLY
432
Oatly Group
OTLY
$439M
| $3.41M | 0.03% |
199,546
+70,125
| +54% | +$1.32M |
|
433
Hain Celestial
HAIN
$53.8M
| $3.34M | 0.03% |
+387,137
| New | +$2.9M |
|
434
National Vision
EYE
$1.83B
| $3.26M | 0.03% |
+299,031
| New | +$3.49M |
|
|
CMPS
435
Compass Pathways
CMPS
$1.81B
| $3.24M | 0.03% |
+514,418
| New | +$3.63M |
|
436
EyePoint Inc
EYPT
$1.07B
| $3.2M | 0.03% |
+400,000
| New | +$3.51M |
|
437
Carlisle Companies
CSL
$15.2B
| $3.15M | 0.03% |
7,013
-10,016
| -59% | -$4.14M |
|
438
Editas Medicine
EDIT
$450M
| $3.07M | 0.03% |
900,421
-70,070
| -7% | -$305K |
|
|
ATYR
439
aTyr Pharma
ATYR
$48.8M
| $2.96M | 0.03% |
1,683,549
+387
| +0% | +$704 |
|
440
TAL Education Group
TAL
$6.78B
| $2.88M | 0.02% |
+243,063
| New | +$2.24M |
|
441
CrowdStrike
CRWD
$208B
| $2.88M | 0.02% |
+41,032
| New | +$2.91M |
|
442
Sana Biotechnology
SANA
$946M
| $2.86M | 0.02% |
687,821
+3,627
| +0.5% | +$19.1K |
|
443
Nkarta
NKTX
$164M
| $2.84M | 0.02% |
629,358
+1,229
| +0.2% | +$6.98K |
|
444
ArriVent BioPharma
AVBP
$1.43B
| $2.84M | 0.02% |
120,944
+20,944
| +21% | +$475K |
|
445
Kura Oncology
KURA
$821M
| $2.8M | 0.02% |
143,207
| – | – |
|
446
Context Therapeutics
CNTX
$46.2M
| $2.67M | 0.02% |
+1,360,682
| New | +$3.02M |
|
447
Western Digital
WDC
$158B
| $2.66M | 0.02% |
51,475
-463,878
| -90% | -$23.4M |
|
|
BIOA
448
BioAge Labs
BIOA
$477M
| $2.6M | 0.02% |
+124,950
| New | +$2.5M |
|
449
Arbutus Biopharma
ABUS
$889M
| $2.57M | 0.02% |
668,153
-258,381
| -28% | -$991K |
|
450
Fabrinet
FN
$19.7B
| $2.57M | 0.02% |
+10,864
| New | +$2.51M |
|
Similar funds
TCIIS
UIM
VAI
KK
Woodline Partners's Q3 2024 Portfolio in Review
As of Q3 2024, Woodline Partners held 747 positions worth $11.9B, up 13% from $10.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Woodline Partners deployed $748M of net new capital in Q3 2024, opening 202 new positions and adding to 220 existing holdings. Its largest new stake was ASML: 149,876 shares worth $125M.
By sector, the portfolio is most concentrated in Healthcare at 43% of assets, up from 42% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Eli Lilly, an estimated $153M trimmed.
- Woodline Partners's largest Q3 2024 buy was ASML: 149,876 shares worth $125M.
- Woodline Partners added most to STMicroelectronics in Q3 2024, an estimated $103M increase.
- Woodline Partners's biggest Q3 2024 reduction was Eli Lilly, cutting an estimated $153M.
- Woodline Partners fully exited TE Connectivity in Q3 2024, selling an estimated $161M.
- Woodline Partners's ten largest holdings make up 12% of its $11.9B portfolio in Q3 2024.
- Woodline Partners opened 202 new positions and closed 161 in Q3 2024.
- Woodline Partners's portfolio value rose 13% quarter-over-quarter to $11.9B.
Based on Woodline Partners's 13F filing for Q3 2024, filed 14 Nov 2024.